Hypothesis:
We hypothesize that PSMA PET-CT in AS patients will improve the diagnostic accuracy of prostate MRI such that a negative PSMA PET-CT will obviate the need for a surveillance prostate biopsy.
Specific Aims:
Define the negative predictive value of PSMA PET-CT in detecting csPCa.
Predict the detection of csPCa with machine learning models using SUV scores from PSMA PET-CT and radiomic features extracted from mpMRI.
Determine the molecular features of localized prostate cancer identified on PSMA PET-CT .
Project Goal:
Our overarching hypothesis is that an anti-CEACAM5 radiotracer for immunoPET imaging will be effective in detection of CEACAM5 expression and will be able to serve as a quantitative in vivo assessment of inter- and perhaps intra-tumoral heterogeneity in patients with prostate cancer (and probably also applicable to other cancers). This approach may serve as a biomarker to describe tumor biology and optimize patient selection for CEACAM5-targeted therapy
Specific Aims:
Using a humanized monoclonal IgG antibody that selectively binds human CEACAM5, we will synthesize zirconium-89 (89Zr)-radiolabeled IgG and evaluate its stability, affinity, specificity, and immunoreactivity in vitro.
Demonstrate use of CEACAM5-directed immunoPET for non-invasive detection of CEACAM5 in NEPC models.
